The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease

Author： Vogt Anja   Parhofer Klaus G  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.6, 2013-04, pp. : 691-697

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Colesevelam: In Pediatric Patients with Heterozygous Familial Hypercholesterolemia

By Perry Caroline M.  

Pediatric Drugs, Vol. 12, Iss. 2, 2010-04 ,pp. : 133-140

Adis International

Access to resources Recommend Favorite

Mipomersen as a potential adjunctive therapy for hypercholesterolemia

By Patel Neeraj   Hegele Robert A  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 15, 2010-10 ,pp. : 2569-2572

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic Potential of Mipomersen in the Management of Familial Hypercholesterolaemia

By Gelsinger Carmen   Steinhagen-Thiessen Elisabeth   Kassner Ursula  

Drugs, Vol. 72, Iss. 11, 2012-07 ,pp. : 1445-1455

Adis International

Access to resources Recommend Favorite

Oxidized-LDL and Paraoxonase-1 As Biomarkers of Coronary Artery Disease in Patients with Sleep-Disordered Breathing

By  

Current Medicinal Chemistry, Vol. 19, Iss. 25, 2012-09 ,pp. : 4359-4366

Bentham Science Publishers

Access to resources Recommend Favorite

Defining the Role of Lipoprotein Apheresis in the Management of Familial Hypercholesterolemia

By >   Datta Borunendra N.   >   Rees Alan   Halcox Julian  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 6, 2011-12 ,pp. : 363-370

Adis International

Access to resources Recommend Favorite